Zymeworks Inc. (ZYME)

USD 12.96

(0.62%)

Long Term Debt Summary of Zymeworks Inc.

Zymeworks Inc.'s latest annual long term debt in 2023 was 22.46 Million USD , down -9.4% from previous year.
Zymeworks Inc.'s latest quarterly long term debt in 2024 Q3 was 17.27 Billion USD , down 0.0% from previous quarter.
Zymeworks Inc. reported annual long term debt of 24.79 Million USD in 2022, down -20.09% from previous year.
Zymeworks Inc. reported annual long term debt of 31.02 Million CAD in 2021, up 422.8% from previous year.
Zymeworks Inc. reported quarterly long term debt of 17.22 Million USD for 2024 Q2, down 0.0% from previous quarter.
Zymeworks Inc. reported quarterly long term debt of 17.27 Billion USD for 2024 Q3, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Zymeworks Inc. (2023 - 2014)

Historical Annual Long Term Debt of Zymeworks Inc. (2023 - 2014)

Year	Long Term Debt	Long Term Debt Growth
2023	22.46 Million USD	-9.4%
2022	24.79 Million USD	-20.09%
2021	31.02 Million CAD	422.8%
2020	5.93 Million USD	5.12%
2019	5.64 Million USD	13340.48%
2018	42 Thousand USD	-19.23%
2017	52 Thousand USD	-98.82%
2016	4.41 Million USD	0.0%
2015	- USD	0.0%
2014	- USD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	21.06 Million USD	0.0%
2024 Q2	17.22 Million USD	0.0%
2024 Q3	17.27 Billion USD	0.0%
2023 Q1	23.96 Million USD	-3.32%
2023 FY	22.46 Million USD	-9.4%
2023 Q4	22.46 Million USD	0.24%
2023 Q3	22.4 Million USD	-5.09%
2023 Q2	23.61 Million USD	-1.49%
2022 Q4	24.79 Million USD	-2.74%
2022 FY	24.79 Million USD	-20.09%
2022 Q3	25.48 Million USD	-12.96%
2022 Q1	30.69 Million USD	-1.07%
2022 Q2	29.28 Million USD	-4.59%
2021 FY	31.02 Million CAD	422.8%
2021 Q4	31.02 Million CAD	7.54%
2021 Q3	28.84 Million USD	-4.49%
2021 Q1	5.44 Million USD	-8.21%
2021 Q2	30.2 Million USD	454.49%
2020 Q2	6.65 Million USD	-9.27%
2020 Q4	5.93 Million USD	-2.63%
2020 Q1	7.33 Million USD	29.94%
2020 Q3	6.09 Million USD	-8.43%
2020 FY	5.93 Million USD	5.12%
2019 Q4	5.64 Million USD	-4.16%
2019 Q3	5.89 Million USD	-5.08%
2019 Q2	6.2 Million USD	-3.74%
2019 Q1	6.44 Million USD	15247.62%
2019 FY	5.64 Million USD	13340.48%
2018 Q1	51 Thousand USD	-1.92%
2018 Q2	48 Thousand USD	-5.88%
2018 Q3	46 Thousand USD	-4.17%
2018 Q4	42 Thousand USD	-8.7%
2018 FY	42 Thousand USD	-19.23%
2017 FY	52 Thousand USD	-98.82%
2017 Q4	52 Thousand USD	0.0%
2017 Q3	- USD	0.0%
2017 Q2	- USD	-100.0%
2017 Q1	4.51 Million USD	2.29%
2016 Q3	3.73 Million USD	0.0%
2016 Q1	- USD	0.0%
2016 Q4	4.41 Million USD	18.35%
2016 FY	4.41 Million USD	0.0%
2015 Q4	- USD	0.0%
2015 FY	- USD	0.0%
2014 FY	- USD	0.0%

Peer Long Term Debt Comparison of Zymeworks Inc.

Name	Long Term Debt	Long Term Debt Difference
ADC Therapeutics SA	112.73 Million USD	80.075%
Alto Neuroscience, Inc.	151.33 Million USD	85.158%
Annovis Bio, Inc.	- USD	-Infinity%
Biohaven Pharmaceutical Holding Company Ltd.	27.56 Million USD	18.528%
Ginkgo Bioworks Holdings, Inc.	221.83 Million USD	89.875%
Nuvation Bio Inc.	2.03 Million USD	-1003.735%
Nuvation Bio Inc.	2.03 Million USD	-1003.735%
Arcus Biosciences, Inc.	110 Million USD	79.581%